Principal Investigator

Peter Grayson, M.D., M.Sc.

Peter Grayson's research interests include clinical and translational research in vasculitis with a focus on biomarker discovery, gene expression profiling, clinical trials, and disease classification.

Vasculitis is a family of rare diseases defined by inflammation in blood vessels. These conditions, if not quickly recognized and properly treated, can cause serious and life-threatening damage to multiple organ systems. The goal of the Vasculitis Translational Research Program (VTRP) is to discover factors that cause vasculitis and to develop novel ways for physicians to diagnose and monitor these diseases more effectively.

Tremendous progress over the last few decades has transformed vasculitis from frequently fatal into a chronic, manageable illness. However, treatment with potentially toxic medications, including steroids and other medications that suppress the immune system, is generally required to induce remission. Although most patients with vasculitis achieve remission with treatment, the majority of patients experience one or more recurrences of the disease. Disease relapse can result in additional permanent organ damage and can be fatal. At present, we have a very crude understanding of what causes vasculitis. There are very few tests available that reliably help a doctor predict which patients will experience a relapsing disease course. The identification of factors that cause vasculitis and the discovery of biomarkers that can predict clinical outcomes and guide patient-specific therapeutic decisions is the major focus of the VTRP.

The VTRP was established in 2013 to evaluate patients with known vasculitis or with clinical suspicion of vasculitis. Diseases of interest include Takayasu’s arteritis (TAK), relapsing polychondritis (RP), giant cell arteritis (GCA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), and polyarteritis nodosa (PAN) among other types of vasculitis.

Current Projects

A selection of our current projects are as follows:

Vascular Imaging in Large-Vessel Vasculitis
Three images visualizing vasculitis in a patient.
Vascular imaging including FDG-PET (left) and magnetic resonance angiography are useful to evaluation vascular inflammation and damage in patients with large-vessel vasculitis.
Takayasu’s arteritis and giant cell arteritis are the two major diseases that affect the aorta and its primary branches. The detection of active vasculitis is important to prevent the progression of vascular disease and organ damage; however, clinical assessment of disease activity is challenging. Although vascular imaging is considered essential in these diseases, there are no accepted guidelines for imaging and prospective imaging data is lacking. Our group has employed advanced molecular imaging techniques in patients with large-vessel vasculitis to study whether serial imaging has diagnostic and prognostic value in addition to monitoring utility. We discovered that the majority of patients with large-vessel vasculitis have evidence of ongoing vascular inflammation by FDG-PET scans during periods of apparent clinical remission and that the degree of vascular inflammation seen during clinical remission predicts future relapse. We developed and validated PETVAS, a quantitative measure of vascular inflammation that is being used internationally as an outcome measure in ongoing clinical trials. Our lab is working to define a potential immunologic basis for subclinical inflammation in these conditions.
Relapsing Polychondritis
Three images visualizing vasculitis in a patient.
Using data-driven classification, we identified three subgroups of patients with relapsing polychondritis based on pattern of organ involvement.
Our group recently established the largest prospective cohort of relapsing polychondritis. The NIH RP program currently has recruited >100 patients with relapsing polychondritis. Patients are evaluated at 6-month intervals using a standardized assessment protocol with biobanking of research samples. From these efforts, we have published some of the only observational cohort data in relapsing polychondritis. Using latent class analysis, we have defined three major clinical subsets of RP based on the pattern of organ involvement. and are using these subsets as the framework to investigate causal disease factors, treatment approaches, and potential biomarkers. Recently, in collaboration with the Kastner lab, we have discovered a genetic factor that is causal in 8% of patients with relapsing polychondritis.
Neutrophil Biology in Small and Medium-Vessel Vasculitis
Color image of neutrophil traps
Neutrophil extracellular traps (NETs) are the by-product of a specific form of cell death. NETs are immunogenic, toxic to the vasculature, and play a role in many forms of vasculitis. In this photo, NETs (long pink strands) are triggered by adenosine in a patient with vasculitis.
Neutrophils are key cells that drive inflammation in many forms of vasculitis. Our group has partnered with the Kaplan Lab in the Systemic Autoimmunity Branch to study novel aspects of neutrophil biology and innate immune system involvement in ANCA-associated vasculitis, drug-induced vasculitis, and monogenic vasculitis. Through these efforts, we have learned that a subset of neutrophils known as low-density granulocytes may play a pathogenic role in ANCA-associated vasculitis, that cholinergic receptors on neutrophils mediate disease in levamisole-induced vasculitis, and that the adenosine-mediated activation of neutrophils contributes to inflammation in deficiency in deaminase 2 (DADA2).


Associate Director NIAMS Fellowship Program
Pastbaccalaureate Fellow
Postdoctoral Fellow (Visiting)
Senior Research Associate
Research Nurse Specialist
Research Nurse Specialist
Staff Clinician
MSRP Scholar
Postbaccalaureate Fellow

Image & Media Gallery

Studies Seeking Patients


Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis

ClinicalTrials.gov Identifier: NCT02257866

Patients with vasculitis or with a suspicion of vasculitis may be eligible to participate in this ongoing research study conducted by the NIAMS Vasculitis Translational Research Program.

To participate, patients may either

  • Provide a mail-in blood sample for genetic studies.
  • Travel to the National Institutes of Health in Bethesda, MD for a comprehensive evaluation.

Participation in our research program typically entails:

  • Comprehensive clinical evaluation by our team of specialists and treatment recommendations. We will communicate with your local doctors about our findings and will remain available over time to help with questions about your care.
  • Donation of blood samples for research.
  • For patients with large-vessel vasculitis, we regularly perform advanced imaging to visualize your arteries, which includes FDG-PET scans to assess vascular inflammation.
  • For patients with relapsing polychondritis, we work closely with our colleagues in Otolaryngology to evaluate your airway.

How to get involved:

  • Patients with vasculitis or their physicians should contact our team research nurse Elaine Novakovich at 301-451-1450 or via email elaine.novakovich@nih.gov
  • Patients with relapsing polychondritis or their physicians should contact our team research nurse Wendy Goodspeed at 301-451-6761 or via email goodspew@mail.nih.gov


Natural History of Coronavirus Disease (COVID-19) in Systemic Autoimmune Diseases

ClinicalTrials.gov Identifier: NCT04690816

Viral infections such as COVID-19 may lead to flare-ups in people with systemic autoimmune diseases (SAD). These infections may also change the function of their immune system and/or cause problems with their blood vessels. Researchers want to learn how people with SAD respond to treatments or vaccines for COVID-19. The objective of this study is to understand how COVID-19 affects inflammation, the immune system, and blood vessels in adults and children with autoimmune diseases.

Scientific Publications

Selected Recent Publications

Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.

Dashora HR, Rosenblum JS, Quinn KA, Alessi H, Novakovich E, Saboury B, Ahlman MA, Grayson P
J Nucl Med.
2021 Jun 4;
pii: jnumed.121.262326. doi: 10.2967/jnumed.121.262326
PMID: 34088771

Mutant UBA1 and Severe Adult-Onset Autoinflammatory Disease. Reply.

Beck DB, Grayson PC, Kastner DL
N Engl J Med.
2021 Jun 3;
doi: 10.1056/NEJMc2102124
PMID: 34077654

VEXAS Syndrome.

Grayson PC, Patel BA, Young NS
2021 May 10;
pii: blood.2021011455. doi: 10.1182/blood.2021011455
PMID: 33971000

Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients with VEXAS Syndrome.

Ferrada MA, Sikora KA, Luo Y, Wells KV, Patel B, Groarke EM, Ospina Cardona D, Rominger E, Hoffmann P, Le MT, Deng Z, Quinn KA, Rose E, Tsai WL, Wigerblad G, Goodspeed W, Jones A, Wilson L, Schnappauf O, Laird RS, Kim J, Allen C, Sirajuddin A, Chen M, Gadina M, Calvo KR, Kaplan MJ, Colbert RA, Aksentijevich I, Young NS, Savic S, Kastner DL, Ombrello AK, Beck DB, Grayson PC
Arthritis Rheumatol.
2021 Mar 28;
doi: 10.1002/art.41743
PMID: 33779074

Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.

Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, Balanda N, Ross DL, Ospina Cardona D, Wu Z, Patel B, Manthiram K, Groarke EM, Gutierrez-Rodrigues F, Hoffmann P, Rosenzweig S, Nakabo S, Dillon LW, Hourigan CS, Tsai WL, Gupta S, Carmona-Rivera C, Asmar AJ, Xu L, Oda H, Goodspeed W, Barron KS, Nehrebecky M, Jones A, Laird RS, Deuitch N, Rowczenio D, Rominger E, Wells KV, Lee CR, Wang W, Trick M, Mullikin J, Wigerblad G, Brooks S, Dell'Orso S, Deng Z, Chae JJ, Dulau-Florea A, Malicdan MCV, Novacic D, Colbert RA, Kaplan MJ, Gadina M, Savic S, Lachmann HJ, Abu-Asab M, Solomon BD, Retterer K, Gahl WA, Burgess SM, Aksentijevich I, Young NS, Calvo KR, Werner A, Kastner DL, Grayson PC
N Engl J Med.
2020 Dec 31;
doi: 10.1056/NEJMoa2026834
PMID: 33108101

Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient-, Physician-, Imaging-, and Laboratory-Based Assessments.

Rimland CA, Quinn KA, Rosenblum JS, Schwartz MN, Bates Gribbons K, Novakovich E, Sreih AG, Merkel PA, Ahlman MA, Grayson PC
Arthritis Care Res (Hoboken).
2020 Sep;
doi: 10.1002/acr.24117
PMID: 31785185

Patterns of clinical presentation in Takayasu's arteritis.

Quinn KA, Gribbons KB, Carette S, Cuthbertson D, Khalidi NA, Koening CL, Langford CA, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Sreih AG, Warrington KJ, Ytterberg SR, Novakovich E, Merkel PA, Grayson PC
Semin Arthritis Rheum.
2020 Aug;
doi: 10.1016/j.semarthrit.2020.04.012
PMID: 32460147


Ferrada MA, Grayson PC
Arthritis Rheumatol.
2020 Dec;
doi: 10.1002/art.41438
PMID: 32686916

Comment on: Derivation of an angiographically based classification system in Takayasu's arteritis: reply.

Goel R, Gribbons KB, Merkel PA, Danda D, Grayson PC
Rheumatology (Oxford).
2020 May 1;
doi: 10.1093/rheumatology/kez659
PMID: 31943122

Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America.

Goel R, Gribbons KB, Carette S, Cuthbertson D, Hoffman GS, Joseph G, Khalidi NA, Koening CL, Kumar S, Langford C, Maksimowicz-McKinnon K, McAlear CA, Monach PA, Moreland LW, Nair A, Pagnoux C, Quinn KA, Ravindran R, Seo P, Sreih AG, Warrington KJ, Ytterberg SR, Merkel PA, Danda D, Grayson PC
Rheumatology (Oxford).
2020 May 1;
doi: 10.1093/rheumatology/kez421
PMID: 31580452

Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone.

Micheletti RG, Pagnoux C, Tamura RN, Grayson PC, McAlear CA, Borchin R, Krischer JP, Merkel PA, Vasculitis Clinical Research Consortium.
2020 Apr 28;
doi: 10.1186/s13063-020-04285-3
PMID: 32345372

Defining Clinical Subgroups in Relapsing Polychondritis: A Prospective Observational Cohort Study.

Ferrada M, Rimland CA, Quinn K, Sikora K, Kim J, Allen C, Sirajuddin A, Goodspeed W, Chen M, Grayson PC
Arthritis Rheumatol.
2020 Aug;
doi: 10.1002/art.41270
PMID: 32249511

Utility of the Brief Illness Perception Questionnaire to Monitor Patient Beliefs in Systemic Vasculitis.

Schwartz MN, Rimland CA, Quinn KA, Ferrada MA, Gribbons KB, Rosenblum JS, Goodspeed W, Novakovich E, Grayson PC
J Rheumatol.
2020 Dec 1;
doi: 10.3899/jrheum.190828
PMID: 32238516

Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort.

Gribbons KB, Ponte C, Craven A, Robson JC, Suppiah R, Luqmani R, Watts R, Merkel PA, Grayson PC
Arthritis Rheumatol.
2020 Apr;
doi: 10.1002/art.41165
PMID: 31729185

Rituximab for chronic periaortitis without evidence of IgG4-related disease: a long-term follow-up study of 20 patients.

Urban ML, Maritati F, Palmisano A, Fenaroli P, Peyronel F, Trivioli G, Ferretti S, De Biase C, Grayson PC, Pegoraro F, Prisco D, Romagnani P, Emmi G, Vaglio A
Ann Rheum Dis.
2020 Mar;
doi: 10.1136/annrheumdis-2019-216258
PMID: 31744824

Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis.

Michailidou D, Rosenblum JS, Rimland CA, Marko J, Ahlman MA, Grayson PC
Ann Rheum Dis.
2020 Feb;
doi: 10.1136/annrheumdis-2019-216145
PMID: 31649025

Imaging acquisition technique influences interpretation of positron emission tomography vascular activity in large-vessel vasculitis.

Quinn KA, Rosenblum JS, Rimland CA, Gribbons KB, Ahlman MA, Grayson PC
Semin Arthritis Rheum.
2020 Feb;
doi: 10.1016/j.semarthrit.2019.07.008
PMID: 31375256

Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis.

Banerjee S, Quinn KA, Gribbons KB, Rosenblum JS, Civelek AC, Novakovich E, Merkel PA, Ahlman MA, Grayson PC
J Rheumatol.
2020 Jan;
doi: 10.3899/jrheum.181222
PMID: 30877209

Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis.

Quinn KA, Gelbard A, Sibley C, Sirajuddin A, Ferrada MA, Chen M, Cuthbertson D, Carette S, Khalidi NA, Koening CL, Langford CA, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Specks U, Sreih AG, Ytterberg SR, Merkel PA, Grayson PC
Rheumatology (Oxford).
2019 Dec 1;
doi: 10.1093/rheumatology/kez217
PMID: 31199488

Patient-perceived Burden of Disease in Pediatric Relapsing Polychondritis.

Rimland CA, Ferrada MA, Sinaii N, Sikora KA, Colbert RA, Grayson PC, Katz JD
J Rheumatol.
2019 Dec;
doi: 10.3899/jrheum.181456
PMID: 31043550

Clinical Factors Associated with Time-Specific Distribution of 18F-Fluorodeoxyglucose in Large-Vessel Vasculitis.

Rosenblum JS, Quinn KA, Rimland CA, Mehta NN, Ahlman MA, Grayson PC
Sci Rep.
2019 Oct 23;
doi: 10.1038/s41598-019-51800-x
PMID: 31645635

Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis.

Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, Khalidi NA, Koening CL, Langford CA, Maksimowicz-McKinnon K, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Quinn KA, Robson JC, Seo P, Sreih AG, Suppiah R, Warrington KJ, Ytterberg SR, Luqmani R, Watts R, Merkel PA, Grayson PC
Arthritis Care Res (Hoboken).
2020 Nov;
doi: 10.1002/acr.24055
PMID: 31444857

Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2.

Carmona-Rivera C, Khaznadar SS, Shwin KW, Irizarry-Caro JA, O'Neil LJ, Liu Y, Jacobson KA, Ombrello AK, Stone DL, Tsai WL, Kastner DL, Aksentijevich I, Kaplan MJ, Grayson PC
2019 Jul 25;
doi: 10.1182/blood.2018892752
PMID: 31015188

Sarcoidosis Concomitant With Takayasu Arteritis, Identified by Advanced Molecular Imaging.

Betancourt BY, Ahlman MA, Grayson PC
Arthritis Rheumatol.
2019 Jun;
doi: 10.1002/art.40847
PMID: 30714676

News & Highlights

Spotlight on Research | November 4, 2020

NIH Researchers Discover a New Inflammatory Disease Called VEXAS

NIH scientists led an international team of researchers toward discovery of a new, adult-onset inflammatory disease abbreviated the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome.
Letter from the Director | February 25, 2016

Building Bridges to Enhance Patient Care: The NIAMS Intramural Research Program

The NIAMS Intramural Research Program (IRP), and the entire intramural program at NIH, offer unique resources in the biomedical research enterprise. The long-term, high-risk, high-reward focus of the IRP allows researchers to stretch the boundaries of innovation. They are able to build bridges across the traditional silos that tend to separate organizations, patients and scientists, and research results and clinical practice. These collaborations make an enormous difference for all Americans.
Research Brief | April 27, 2015

Potential Biomarker for Treatment Response in Vasculitis Patients Identified

Scientists have discovered a potential biomarker for predicting which patients with a disease known as ANCA-associated vasculitis (AAV) are more likely to respond to treatment.
Last Updated: June 2021 Back to Top